Biogen hauls in $6B amid biopharma's M&A fever pitch

Days after Gilead Sciences ($GILD) spurred a wave of buyout rumors with its effort to bring in $10 billion, Biogen ($BIIB) laid out plans to raise $6 billion of its own, providing few details as it looks to bolster its cash position. The Cambridge, MA, drugmaker priced four series of senior notes, maturing between 2020 and 2045, in an offering expected to close next week. Some of the money will go toward a previously announced share repurchase program, the company said, with the rest tabbed for the vague "working capital and other general corporate purposes." More

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.